key: cord-0023249-3tbep3mk
authors: Lytvyn, Yuliya; Mufti, Asfandyar; Zaaroura, Hiba; Sachdeva, Muskaan; Lu, Justin D.; Rankin, Brian D.; Prajapati, Vimal H.; Vender, Ronald; Yeung, Jensen
title: Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
date: 2021-11-09
journal: JAAD Int
DOI: 10.1016/j.jdin.2021.09.007
sha: 4a030025dfc4b46f42f2c1162362f745a1a000fb
doc_id: 23249
cord_uid: 3tbep3mk

nan

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study

To the Editor: Risankizumab is a humanized IgG1 monoclonal antibody that binds to the p19 subunit of interleukin 23 with remarkable safety and efficacy for treatment of moderate-to-severe plaque psoriasis in phase 3 randomized controlled trials (RCTs). 1-3 Data on how findings from RCTs translate to real-world experience are limited. 4 To better understand the safety and efficacy of risankizumab at 16 weeks in clinical practice, a retrospective chart review was conducted at 5 academic centers and 2 community practices in Canada.

Charts of patients with moderate-to-severe plaque psoriasis treated with subcutaneous injections of risankizumab (150 mg at weeks 0 and 4, then every 12 weeks thereafter) were reviewed. Psoriasis Area and Severity Index (PASI) and/or Physician Global Assessment (PGA) scores after 16 weeks of risankizumab treatment were collected. Risankizumab efficacy outcomes were defined as met if one of the following criteria was achieved: a 75% reduction in PASI (PASI75) or a PGA score of 0 (clear) or 1 (almost clear) (PGA 0/ 1) when PASI was not documented. Safety was assessed by patient-reported adverse events (AEs). Institutional review board approval was obtained for the conduct of this study (Sunnybrook Health Sciences Centre:205-2018; Women's College Hospital:2018-0079-E).

Eighty-three patients (male, 61.4%; mean age, 48.7 6 15.5 years) were included in the analysis with a baseline PASI of 10.0 6 5.8, PGA of 3.2 6 0.8, and body surface area involvement of 11.9 6 12.7% (Table I) . Common previously failed treatments included topical therapy (92.8%), phototherapy (55.4%), methotrexate (41.0%) and apremilast (22.9%); 56.6% were biologic-naive. The most common previously failed biologics were ustekinumab (15.7%) and adalimumab (15.7%). Overall, 71 of 83 patients (85.5%) met the primary efficacy end point of PASI75 or PGA 0/1 at week 16. Of the 47 biologicnaive patients, 43 (91.5%) responded to risankizumab and of the 36 patients that previously failed biologic therapy, 28 (77.8%) responded to risankizumab. Of the 13 patients with prior failure to Previous real world evidence with other biologics suggests that efficacy may differ when compared to phase 3 clinical trials, likely due to the exclusion of medically challenging patients such as those who had failed prior biologics in clinical trials. 5 In this regard, 56.6% of the patients in our cohort were biologic-naive, similar to the 59% to 66% reported in phase 3 clinical trials. 1 Consequently, our data show that in clinical practice, a similar proportion of patients (85.5%) responded to risankizumab compared to its phase 3 clinical trials which reported 83.7% to 87.8% of patients achieving PGA 0/1 after 16 weeks of treatment. 1 Our study, however, is limited by heterogenous data, modest sample size, follow-up time, and lack of a control group.

In summary, the safety and efficacy of risankizumab for the treatment of plaque psoriasis in clinical practice was comparable to that reported in RCTs. Larger studies are needed to confirm our results. 

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (Ul-tIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-tosevere plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial

Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic

Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis

speaker at events sponsored by AbbVie, Amgen, Boehringer Ingelheim, Celgene, Galderma, GSK, Janssen, LEO Pharma, Eli Lilly, MSD, Novartis, UCB, and Pfizer. Dr. Vimal H. Prajapati has been an advisor, consultant, investigator and/or speaker for AbbVie, Actelion, Amgen, Aralez, Arcutis, Asana, Aspen, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Cipher, Concert, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, Janssen, LEO Pharma, L'Oreal, Medexus, Novartis, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, UCB, and Valeant.